首页 > 最新文献

Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery最新文献

英文 中文
[Distal transradial access for non-coronary endovascular restrictions]. [非冠状动脉血管内限制的远端经桡动脉通路]。
Q3 Medicine Pub Date : 2025-09-30 DOI: 10.33029/1027-6661-2025-31-3-117-121
Ya A Khudyakov, R N Komarov, Ph Yu Kopylov, D N Samochatov, D G Gognieva, N A Ershova

Objective: To evaluate the possibility of using distal transradial access in routine practice for emergency and elective non-coronary endovascular interventions.

Patients and methods: The results of the use of distal transradial access were studied in patients who underwent endovascular interventions for gastrointestinal bleeding, renal bleeding in a complicated course of angiomyolipoma, traumatic injury to the spleen accompanied by bleeding, uterine leiomyomas, abnormal uterine bleeding, ectopic pregnancy, bleeding in cancer process in the pelvic organs. The study included 78 patients.

Results: The use of distal transradial access demonstrated the results comparable to those of the access to the radial artery in the classical form.

Conclusion: The distal transradial approach is a reliable and safe site of arterial access in patients who require strict control of hemostasis in combination with minimal risk of bleeding, also making it possible to maintain patency of the radial artery for future use as an arterial conduit.

目的:探讨急诊和选择性非冠状动脉血管内介入治疗中桡动脉远端经桡动脉通路的可行性。患者与方法:研究经桡骨远端通路在消化道出血、血管平滑肌脂肪瘤并发肾出血、外伤性脾损伤伴出血、子宫平滑肌瘤、子宫异常出血、宫外孕、盆腔脏器癌变过程出血等血管内介入治疗中的应用效果。该研究包括78名患者。结果:桡动脉远端经桡动脉通路的使用与经典形式桡动脉通路的效果相当。结论:桡动脉远端入路对于需要严格控制止血且出血风险最小的患者是一种可靠、安全的动脉入路,也可以维持桡动脉的通畅,以便将来作为动脉导管使用。
{"title":"[Distal transradial access for non-coronary endovascular restrictions].","authors":"Ya A Khudyakov, R N Komarov, Ph Yu Kopylov, D N Samochatov, D G Gognieva, N A Ershova","doi":"10.33029/1027-6661-2025-31-3-117-121","DOIUrl":"https://doi.org/10.33029/1027-6661-2025-31-3-117-121","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the possibility of using distal transradial access in routine practice for emergency and elective non-coronary endovascular interventions.</p><p><strong>Patients and methods: </strong>The results of the use of distal transradial access were studied in patients who underwent endovascular interventions for gastrointestinal bleeding, renal bleeding in a complicated course of angiomyolipoma, traumatic injury to the spleen accompanied by bleeding, uterine leiomyomas, abnormal uterine bleeding, ectopic pregnancy, bleeding in cancer process in the pelvic organs. The study included 78 patients.</p><p><strong>Results: </strong>The use of distal transradial access demonstrated the results comparable to those of the access to the radial artery in the classical form.</p><p><strong>Conclusion: </strong>The distal transradial approach is a reliable and safe site of arterial access in patients who require strict control of hemostasis in combination with minimal risk of bleeding, also making it possible to maintain patency of the radial artery for future use as an arterial conduit.</p>","PeriodicalId":7821,"journal":{"name":"Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery","volume":"31 3","pages":"117-121"},"PeriodicalIF":0.0,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147430282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Embolization of high-flow arteriovenous malformations against adenosine-induced cardioplegia with non-adhesive embolizing agents]. [用非粘连栓剂栓塞高流量动静脉畸形对抗腺苷诱导的心脏骤停]。
Q3 Medicine Pub Date : 2025-09-30 DOI: 10.33029/1027-6661-2025-31-3-78-85
A E Petrov, L V Rozhchenko, S A Goroshchenko, N A Mamonov, V V Bobinov, I S Terekhov, K A Samochernykh
{"title":"[Embolization of high-flow arteriovenous malformations against adenosine-induced cardioplegia with non-adhesive embolizing agents].","authors":"A E Petrov, L V Rozhchenko, S A Goroshchenko, N A Mamonov, V V Bobinov, I S Terekhov, K A Samochernykh","doi":"10.33029/1027-6661-2025-31-3-78-85","DOIUrl":"https://doi.org/10.33029/1027-6661-2025-31-3-78-85","url":null,"abstract":"","PeriodicalId":7821,"journal":{"name":"Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery","volume":"31 3","pages":"78-85"},"PeriodicalIF":0.0,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147430330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Neovasculgen® - has its effectiveness been proven? (Audiatur et altera pars)]. [Neovasculgen®-其有效性已被证实吗?](Audiatur和altera pars)。
Q3 Medicine Pub Date : 2025-09-30 DOI: 10.33029/1027-6661-2025-31-3-16-19
A N Vachev, V V Bazylev, A V Troitskiy, A A Karpenko

This work is controversial. It addresses only one question: is there a convincing evidence base at this stage of development on the positive effect of the already registered drug Neovasculgen® on the course of chronic lower limb ischemia in atherosclerotic lesions of the main vessels. Conclusion. At the present stage, the evidence base on the benefits of using Neovasculgen® is insufficient to include this drug as a recommended therapeutic agent in the National Clinical Guidelines.

这项工作是有争议的。它只解决了一个问题:在这个发展阶段,是否有令人信服的证据表明已经注册的药物Neovasculgen®对主要血管粥样硬化病变的慢性下肢缺血的积极作用?结论。在目前阶段,基于使用Neovasculgen®的益处的证据还不足以将该药物作为推荐治疗药物纳入国家临床指南。
{"title":"[Neovasculgen® - has its effectiveness been proven? (Audiatur et altera pars)].","authors":"A N Vachev, V V Bazylev, A V Troitskiy, A A Karpenko","doi":"10.33029/1027-6661-2025-31-3-16-19","DOIUrl":"10.33029/1027-6661-2025-31-3-16-19","url":null,"abstract":"<p><p>This work is controversial. It addresses only one question: is there a convincing evidence base at this stage of development on the positive effect of the already registered drug Neovasculgen® on the course of chronic lower limb ischemia in atherosclerotic lesions of the main vessels. Conclusion. At the present stage, the evidence base on the benefits of using Neovasculgen® is insufficient to include this drug as a recommended therapeutic agent in the National Clinical Guidelines.</p>","PeriodicalId":7821,"journal":{"name":"Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery","volume":"31 3","pages":"16-19"},"PeriodicalIF":0.0,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147430318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Distal embolism during endovascular and hybrid reconstruction of extensive occlusion of the superficial femoral artery]. [股浅动脉广泛闭塞的血管内混合式重建中的远端栓塞]。
Q3 Medicine Pub Date : 2025-06-02 DOI: 10.33029/1027-6661-2025-31-2-18-25
A A Gostev, O S Osipova, A V Cheban, O E Frykina, A A Karpenko

Objective: The purpose of this study was to compare the incidence of distal embolization during two procedures of restoring blood flow through the superficial femoral artery (SFA): endovascular recanalization and open endarterectomy, both supplemented with paclitaxel-coated balloon angioplasty.

Patients and methods: Our prospective, randomized, single-center pilot study included 20 patients diagnosed as having extensive occlusions of the SFA. Group 1 patients (n=10) underwent SFA recanalization using percutaneous transluminal angioplasty with a drug-coated balloon (PTA + DCB). Group 2 patients (n=10) underwent semiclosed loop endarterectomy (LE) from the SFA followed by drug-coated balloon angioplasty (LE + DCB). Doppler ultrasonography was used to detect emboli during the revascularization procedure.

Results: The patients had no statistically significant differences in age, concomitant pathology, and severity of lower limb ischemia. The majority of patients had Rutherford class 3 chronic limb ischemia. The median number of emboli during the procedure in Group 1 and Group 2 patients amounted to 200.0 [100.0; 200.0] and 7 [6; 8], respectively, p=0.0002. Moreover, in Group 1, peripheral embolism occurred both during recanalization of the target artery (in 100% of cases) and during drug-coated balloon angioplasty (in 60% of cases), whereas in Group 2, peripheral embolism occurred only during drug-coated balloon angioplasty (100% of cases).

Conclusion: Endovascular recanalization of long-segment SFA occlusions followed by DCB angioplasty (PTA + DCB) was associated with a higher incidence of material distal embolism compared with the hybrid technique (LE + DCB).

目的:本研究的目的是比较两种通过股浅动脉(SFA)恢复血流的手术中远端栓塞的发生率:血管内再通术和开放动脉内膜切除术,两者都辅以紫杉醇包被球囊血管成形术。患者和方法:我们的前瞻性、随机、单中心试点研究纳入了20例诊断为SFA广泛闭塞的患者。第1组患者(n=10)采用药物包被球囊(PTA + DCB)经皮腔内血管成形术行SFA再通。组2患者(n=10)行SFA半闭环动脉内膜切除术(LE),随后行药物包被球囊血管成形术(LE + DCB)。在血运重建术中使用多普勒超声检查栓塞。结果:两组患者在年龄、伴发病理、下肢缺血严重程度等方面无统计学差异。大多数患者为Rutherford 3级慢性肢体缺血。1组和2组患者术中栓塞中位数为200.0 [100.0;200.0]和7 [6;8], p=0.0002。此外,在1组中,外周栓塞发生在靶动脉再通(100%的病例)和药物包被球囊血管成形术(60%的病例)期间,而在2组中,外周栓塞仅发生在药物包被球囊血管成形术期间(100%的病例)。结论:与混合技术(LE + DCB)相比,长段SFA闭塞血管内再通术后DCB血管成形术(PTA + DCB)的物质远端栓塞发生率更高。
{"title":"[Distal embolism during endovascular and hybrid reconstruction of extensive occlusion of the superficial femoral artery].","authors":"A A Gostev, O S Osipova, A V Cheban, O E Frykina, A A Karpenko","doi":"10.33029/1027-6661-2025-31-2-18-25","DOIUrl":"https://doi.org/10.33029/1027-6661-2025-31-2-18-25","url":null,"abstract":"<p><strong>Objective: </strong>The purpose of this study was to compare the incidence of distal embolization during two procedures of restoring blood flow through the superficial femoral artery (SFA): endovascular recanalization and open endarterectomy, both supplemented with paclitaxel-coated balloon angioplasty.</p><p><strong>Patients and methods: </strong>Our prospective, randomized, single-center pilot study included 20 patients diagnosed as having extensive occlusions of the SFA. Group 1 patients (n=10) underwent SFA recanalization using percutaneous transluminal angioplasty with a drug-coated balloon (PTA + DCB). Group 2 patients (n=10) underwent semiclosed loop endarterectomy (LE) from the SFA followed by drug-coated balloon angioplasty (LE + DCB). Doppler ultrasonography was used to detect emboli during the revascularization procedure.</p><p><strong>Results: </strong>The patients had no statistically significant differences in age, concomitant pathology, and severity of lower limb ischemia. The majority of patients had Rutherford class 3 chronic limb ischemia. The median number of emboli during the procedure in Group 1 and Group 2 patients amounted to 200.0 [100.0; 200.0] and 7 [6; 8], respectively, p=0.0002. Moreover, in Group 1, peripheral embolism occurred both during recanalization of the target artery (in 100% of cases) and during drug-coated balloon angioplasty (in 60% of cases), whereas in Group 2, peripheral embolism occurred only during drug-coated balloon angioplasty (100% of cases).</p><p><strong>Conclusion: </strong>Endovascular recanalization of long-segment SFA occlusions followed by DCB angioplasty (PTA + DCB) was associated with a higher incidence of material distal embolism compared with the hybrid technique (LE + DCB).</p>","PeriodicalId":7821,"journal":{"name":"Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery","volume":"31 2","pages":"18-25"},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147430061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Intraarterial intrathrombus thrombolysis with non-immunogenic staphylokinase vs surgery in patients with acute limb ischemia: protocol of a multicenter, open-label, randomized clinical trial FORAT]. [非免疫原性葡萄激酶在急性肢体缺血患者的动脉血栓溶栓与手术:一项多中心、开放标签、随机临床试验的方案]。
Q3 Medicine Pub Date : 2025-06-02 DOI: 10.33029/1027-6661-2025-31-2-33-41
I I Zatevakhin, A V Chupin, A A Karpenko, A V Savello, V N Zolkin, E B Yarovaya, V A Kutsenko, S V Ivanov, M P Semenov, A M Semenov, S S Markin

Objective: The aim of the FORAT clinical trial is to evaluate the efficacy and safety of intra-arterial intrathrombus administration of recombinant non-immunogenic staphylokinase in patients with acute limb ischemia vs surgery.

Patients and methods: Non-immunogenic staphylokinase has high thrombolytic activity and fibrin selectivity. The FORAT clinical trial is a randomized, open-label, multicenter, comparative study in two parallel groups. At the clinical sites, eligible patients (with a recruitment target of 170 subjects, taking into account a possible 10% dropout) diagnosed as having grade I-IIb acute limb ischemia will be equally randomized by the 'envelope' method into two groups assigned to receive either non-immunogenic staphylokinase or undergo surgical intervention. Surgical methods of treatment are taken to mean the possibility of endovascular intervention, open surgery and/or bypass surgery in accordance with the current National Guidelines, depending on the accepted tactics of patient management in the clinical center and the patient's condition. The study protocol presents the inclusion and exclusion criteria, sample size estimation, and the plan of the trial. The primary efficacy endpoint is the number of patients without amputations at day 30. Safety criteria will be defined as cases of hemorrhagic stroke, bleeding according to the BARC criteria (types 3 and 5), the incidence of adverse events and lethal outcomes within 30 days of follow-up.

Results: Based on the results of the study, data will be obtained on the efficacy and safety of intra-arterial thrombolysis administration of non-immunogenic staphylokinase in patients with acute limb versus surgical methods of treatment. A report will be drawn up with attachments of individual data and statistical analysis of the results. The findings of the study will be published and presented at conferences.

Registration: The FORAT trial protocol was approved by the Ministry of Health of Russia No. 184 dated March 18, 2022, the Ethics Council of the Ministry of Health of Russia No. 303 dated March 1, 2022, and registered at clinicaltrials.gov No. NCT05372718 (FORAT).

目的:FORAT临床试验的目的是评估重组非免疫原性葡萄激酶在急性肢体缺血患者动脉血栓内给药的疗效和安全性。患者和方法:非免疫原性葡萄激酶具有高溶栓活性和纤维蛋白选择性。FORAT临床试验是一项随机、开放标签、多中心、两个平行组的比较研究。在临床现场,诊断为I-IIb级急性肢体缺血的符合条件的患者(招募目标为170名,考虑到可能有10%的受试者退出)将通过“包络”方法平均随机分为两组,分别接受非免疫原性葡萄激酶治疗或接受手术干预。手术治疗方法是指血管内介入、开放手术和/或搭桥手术的可能性,根据目前的国家指南,取决于临床中心接受的患者管理策略和患者的病情。研究方案包括纳入和排除标准、样本量估计和试验计划。主要疗效终点是第30天未截肢的患者数量。安全标准将定义为出血性卒中病例,根据BARC标准出血(3型和5型),不良事件的发生率和随访30天内的致死结果。结果:根据研究结果,将获得非免疫原性葡萄激酶动脉溶栓治疗急性肢体患者与手术治疗方法的疗效和安全性的数据。将编制一份报告,并附上个别数据和结果的统计分析。这项研究的结果将在会议上发表和介绍。注册:俄罗斯卫生部于2022年3月18日第184号批准了FORAT试验方案,俄罗斯卫生部伦理委员会于2022年3月1日第303号批准了FORAT试验方案,并在clinicaltrials.gov上注册了该方案。NCT05372718 (FORAT)。
{"title":"[Intraarterial intrathrombus thrombolysis with non-immunogenic staphylokinase vs surgery in patients with acute limb ischemia: protocol of a multicenter, open-label, randomized clinical trial FORAT].","authors":"I I Zatevakhin, A V Chupin, A A Karpenko, A V Savello, V N Zolkin, E B Yarovaya, V A Kutsenko, S V Ivanov, M P Semenov, A M Semenov, S S Markin","doi":"10.33029/1027-6661-2025-31-2-33-41","DOIUrl":"10.33029/1027-6661-2025-31-2-33-41","url":null,"abstract":"<p><strong>Objective: </strong>The aim of the FORAT clinical trial is to evaluate the efficacy and safety of intra-arterial intrathrombus administration of recombinant non-immunogenic staphylokinase in patients with acute limb ischemia vs surgery.</p><p><strong>Patients and methods: </strong>Non-immunogenic staphylokinase has high thrombolytic activity and fibrin selectivity. The FORAT clinical trial is a randomized, open-label, multicenter, comparative study in two parallel groups. At the clinical sites, eligible patients (with a recruitment target of 170 subjects, taking into account a possible 10% dropout) diagnosed as having grade I-IIb acute limb ischemia will be equally randomized by the 'envelope' method into two groups assigned to receive either non-immunogenic staphylokinase or undergo surgical intervention. Surgical methods of treatment are taken to mean the possibility of endovascular intervention, open surgery and/or bypass surgery in accordance with the current National Guidelines, depending on the accepted tactics of patient management in the clinical center and the patient's condition. The study protocol presents the inclusion and exclusion criteria, sample size estimation, and the plan of the trial. The primary efficacy endpoint is the number of patients without amputations at day 30. Safety criteria will be defined as cases of hemorrhagic stroke, bleeding according to the BARC criteria (types 3 and 5), the incidence of adverse events and lethal outcomes within 30 days of follow-up.</p><p><strong>Results: </strong>Based on the results of the study, data will be obtained on the efficacy and safety of intra-arterial thrombolysis administration of non-immunogenic staphylokinase in patients with acute limb versus surgical methods of treatment. A report will be drawn up with attachments of individual data and statistical analysis of the results. The findings of the study will be published and presented at conferences.</p><p><strong>Registration: </strong>The FORAT trial protocol was approved by the Ministry of Health of Russia No. 184 dated March 18, 2022, the Ethics Council of the Ministry of Health of Russia No. 303 dated March 1, 2022, and registered at clinicaltrials.gov No. NCT05372718 (FORAT).</p>","PeriodicalId":7821,"journal":{"name":"Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery","volume":"31 2","pages":"33-41"},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147430040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Predictors of aneurysmal sac growth after endovascular aortic repair]. 血管内主动脉修复后动脉瘤囊生长的预测因素。
Q3 Medicine Pub Date : 2025-06-02 DOI: 10.33029/1027-6661-2025-31-2-26-32
R S Polyakov, K A Kur-Ipa, Sh G Chargazia, M V Puretskiy, Yu M Saakyan, G V Mardanyan, A A Pirkova, V M Safonova, M V Karuk, S A Abugov

Relevance: The growth of the aneurysmal sac after endovascular treatment of infrarenal abdominal aortic aneurysms remains a significant problem associated with the risk of late complications. Identifying reliable predictors of this process is essential for improving long-term treatment outcomes. The aim to evaluate the predictors of aneurysmal sac growth after endovascular treatment of infrarenal abdominal aortic aneurysms.

Material and methods: A retrospective study was conducted on 214 patients who underwent endovascular treatment of infrarenal abdominal aortic aneurysms between 2017 and 2023. Patients were divided into two groups: those with aneurysm regression or stability (n=180) and those with aneurysm growth (n=34). Clinical, demographic, anatomical, and technical predictors of sac growth were assessed.

Results: It was found that the most significant factors influencing aneurysmal sac growth were the initial aneurysm diameter, the volume of its patent lumen, and the patency of the inferior mesenteric artery. Some patients with a stable aneurysm diameter showed an increase in sac volume of more than 10%.

Conclusion: Measuring the volume of the aneurysmal sac allows for the identification of patients at risk of disease progression, even when the aneurysm diameter remains stable. The identified predictors will improve the results of endovascular treatment of infrarenal abdominal aortic aneurysms.

相关性:肾下腹主动脉瘤血管内治疗后动脉瘤囊的生长仍然是一个与晚期并发症风险相关的重要问题。确定这一过程的可靠预测因素对于改善长期治疗结果至关重要。目的探讨颅内腹主动脉瘤血管内治疗后动脉瘤囊生长的预测因素。材料与方法:回顾性分析2017 - 2023年间214例经血管内治疗的肾下腹主动脉瘤患者。将患者分为两组:动脉瘤消退或稳定组(180例)和动脉瘤生长组(34例)。评估囊生长的临床、人口统计学、解剖学和技术预测因素。结果:影响动脉瘤囊生长最显著的因素是动脉瘤初始直径、未闭腔容积和肠系膜下动脉通畅程度。一些动脉瘤直径稳定的患者囊体积增加超过10%。结论:测量动脉瘤囊的体积可以识别有疾病进展风险的患者,即使动脉瘤直径保持稳定。确定的预测因子将改善肾下腹主动脉瘤血管内治疗的结果。
{"title":"[Predictors of aneurysmal sac growth after endovascular aortic repair].","authors":"R S Polyakov, K A Kur-Ipa, Sh G Chargazia, M V Puretskiy, Yu M Saakyan, G V Mardanyan, A A Pirkova, V M Safonova, M V Karuk, S A Abugov","doi":"10.33029/1027-6661-2025-31-2-26-32","DOIUrl":"https://doi.org/10.33029/1027-6661-2025-31-2-26-32","url":null,"abstract":"<p><strong>Relevance: </strong>The growth of the aneurysmal sac after endovascular treatment of infrarenal abdominal aortic aneurysms remains a significant problem associated with the risk of late complications. Identifying reliable predictors of this process is essential for improving long-term treatment outcomes. The aim to evaluate the predictors of aneurysmal sac growth after endovascular treatment of infrarenal abdominal aortic aneurysms.</p><p><strong>Material and methods: </strong>A retrospective study was conducted on 214 patients who underwent endovascular treatment of infrarenal abdominal aortic aneurysms between 2017 and 2023. Patients were divided into two groups: those with aneurysm regression or stability (n=180) and those with aneurysm growth (n=34). Clinical, demographic, anatomical, and technical predictors of sac growth were assessed.</p><p><strong>Results: </strong>It was found that the most significant factors influencing aneurysmal sac growth were the initial aneurysm diameter, the volume of its patent lumen, and the patency of the inferior mesenteric artery. Some patients with a stable aneurysm diameter showed an increase in sac volume of more than 10%.</p><p><strong>Conclusion: </strong>Measuring the volume of the aneurysmal sac allows for the identification of patients at risk of disease progression, even when the aneurysm diameter remains stable. The identified predictors will improve the results of endovascular treatment of infrarenal abdominal aortic aneurysms.</p>","PeriodicalId":7821,"journal":{"name":"Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery","volume":"31 2","pages":"26-32"},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147430045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Therapeutic policy in a patient with an abdominal aortic aneurysm and gastric cancer (case report)]. [1例腹主动脉瘤合并胃癌患者的治疗策略(附病例报告)]。
Q3 Medicine Pub Date : 2025-06-02 DOI: 10.33029/1027-6661-2025-31-2-42-46
A P Krasnikov, D V Kozlov, I V Isaeva, K D Dalgatov, B A Pomortsev, Yu R Alborov

Presented herein is a clinical case report regarding successful surgical treatment of a patient for stage III stomach cancer and an infrarenal abdominal aortic aneurysm. Such a combination is a sufficiently rare and complicated clinical situation. The treatment was performed by a multidisciplinary team. The chosen policy of a simultaneous operation made it possible to reduce the time to initiating a course of chemotherapy.

本文报告一个成功的手术治疗III期胃癌和肾下腹主动脉瘤的临床病例。这种合并是一种非常罕见和复杂的临床情况。治疗是由一个多学科团队进行的。选择同时手术的策略可以减少开始一个疗程化疗的时间。
{"title":"[Therapeutic policy in a patient with an abdominal aortic aneurysm and gastric cancer (case report)].","authors":"A P Krasnikov, D V Kozlov, I V Isaeva, K D Dalgatov, B A Pomortsev, Yu R Alborov","doi":"10.33029/1027-6661-2025-31-2-42-46","DOIUrl":"https://doi.org/10.33029/1027-6661-2025-31-2-42-46","url":null,"abstract":"<p><p>Presented herein is a clinical case report regarding successful surgical treatment of a patient for stage III stomach cancer and an infrarenal abdominal aortic aneurysm. Such a combination is a sufficiently rare and complicated clinical situation. The treatment was performed by a multidisciplinary team. The chosen policy of a simultaneous operation made it possible to reduce the time to initiating a course of chemotherapy.</p>","PeriodicalId":7821,"journal":{"name":"Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery","volume":"31 2","pages":"42-46"},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147430293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Artificial intelligence in medicine: history, current status and future directions of research]. [医学中的人工智能:历史、现状与未来研究方向]。
Q3 Medicine Pub Date : 2025-06-02 DOI: 10.33029/1027-6661-2025-31-2-47-56
A V Svetlikov, O O Khudozhnikova, V S Gurevich, A V Kebriakov, V A Ratnikov, P P Yablonskii, V M Melnikov, P K Yablonskiy

The article is devoted to the use of artificial intelligence in medicine. The advantages, disadvantages, and prospects of its application, including in robotic surgery, are outlined. An excursion into the history of the origin and formation of artificial intelligence is also made.

这篇文章专门讨论人工智能在医学中的应用。概述了其优点、缺点和应用前景,包括在机器人手术中的应用。对人工智能的起源和形成的历史也做了一个短途旅行。
{"title":"[Artificial intelligence in medicine: history, current status and future directions of research].","authors":"A V Svetlikov, O O Khudozhnikova, V S Gurevich, A V Kebriakov, V A Ratnikov, P P Yablonskii, V M Melnikov, P K Yablonskiy","doi":"10.33029/1027-6661-2025-31-2-47-56","DOIUrl":"https://doi.org/10.33029/1027-6661-2025-31-2-47-56","url":null,"abstract":"<p><p>The article is devoted to the use of artificial intelligence in medicine. The advantages, disadvantages, and prospects of its application, including in robotic surgery, are outlined. An excursion into the history of the origin and formation of artificial intelligence is also made.</p>","PeriodicalId":7821,"journal":{"name":"Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery","volume":"31 2","pages":"47-56"},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147430044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Carotid artery occlusion and stenosis (Russian experts' guidelines)]. [颈动脉闭塞和狭窄(俄罗斯专家指南)]。
Q3 Medicine Pub Date : 2025-06-02 DOI: 10.33029/1027-6661-2025-31-2-57-158
V S Arakelyan, I N Shchanitsyn, K A Andreychuk, T V Balakhonova, V L Baldin, A N Vachev, R A Vinogradov, O V Dmitriev, V P Kulikov, A V Makarov, A V Maksimov, I O Panov, S A Papoyan, A V Svetlikov, G Yu Sokurenko, I A Suchkov, I E Timina, A V Troitsky, A A Fokin, A O Chechetkin, L E Shulgina, M V Shumilina, S A Abugov, R S Akchurin, B G Alekyan, V V Akhmetov, Yu V Belov, D F Beloyartsev, A V Gavrilenko, T E Imaev, Z A Kavteladze, R E Kalinin, A A Karpenko, A V Matyushkin, E R Charchyan, A V Chupin

The guidelines have been developed in accordance with the requirements of the Ministry of health of the Russian Federation by the All-Russian public organization 'Russian Society of Angiologists and Vascular Surgeons' with the participation of the Association of Cardiovascular Surgeons of Russia, the All-Russian Scientific Society of Cardiology, the Russian Scientific Society of Endovascular Therapies, and the Russian Association of Specialists in Ultrasound Diagnostics in Medicine. Coding according to the International Statistical Classification of Diseases and Related Health Problems: I65.2, I65.3, I65.9, I70.8. Age group - children and adults.

根据俄罗斯联邦卫生部的要求,全俄公共组织“俄罗斯血管学家和血管外科医生协会”在俄罗斯心血管外科医生协会、全俄心脏病学科学学会、俄罗斯血管内治疗科学学会和俄罗斯医学超声诊断专家协会的参与下制定了该指南。根据疾病和相关健康问题国际统计分类编码:I65.2, I65.3, I65.9, I70.8。年龄组-儿童和成人。
{"title":"[Carotid artery occlusion and stenosis (Russian experts' guidelines)].","authors":"V S Arakelyan, I N Shchanitsyn, K A Andreychuk, T V Balakhonova, V L Baldin, A N Vachev, R A Vinogradov, O V Dmitriev, V P Kulikov, A V Makarov, A V Maksimov, I O Panov, S A Papoyan, A V Svetlikov, G Yu Sokurenko, I A Suchkov, I E Timina, A V Troitsky, A A Fokin, A O Chechetkin, L E Shulgina, M V Shumilina, S A Abugov, R S Akchurin, B G Alekyan, V V Akhmetov, Yu V Belov, D F Beloyartsev, A V Gavrilenko, T E Imaev, Z A Kavteladze, R E Kalinin, A A Karpenko, A V Matyushkin, E R Charchyan, A V Chupin","doi":"10.33029/1027-6661-2025-31-2-57-158","DOIUrl":"10.33029/1027-6661-2025-31-2-57-158","url":null,"abstract":"<p><p>The guidelines have been developed in accordance with the requirements of the Ministry of health of the Russian Federation by the All-Russian public organization 'Russian Society of Angiologists and Vascular Surgeons' with the participation of the Association of Cardiovascular Surgeons of Russia, the All-Russian Scientific Society of Cardiology, the Russian Scientific Society of Endovascular Therapies, and the Russian Association of Specialists in Ultrasound Diagnostics in Medicine. Coding according to the International Statistical Classification of Diseases and Related Health Problems: I65.2, I65.3, I65.9, I70.8. Age group - children and adults.</p>","PeriodicalId":7821,"journal":{"name":"Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery","volume":"31 2","pages":"57-158"},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147430079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Surgical treatment of thoracic aortic aneurysms: historical pages]. 胸主动脉瘤的外科治疗:历史文献。
Q3 Medicine Pub Date : 2025-06-02 DOI: 10.33029/1027-6661-2025-31-2-7-17
D S Panfilov, B N Kozlov

The article discusses the main historical events related to the diagnosis and treatment of thoracic aortic aneurysms, tracing the evolution of surgical approaches in patients with this pathology, as well as describing the facts and events that influenced the development of thoracic aortic surgery as an independent branch of cardiovascular surgery.

本文讨论了与胸主动脉瘤的诊断和治疗相关的主要历史事件,追溯了这种病理患者的手术方法的演变,并描述了影响胸主动脉瘤手术作为心血管外科独立分支发展的事实和事件。
{"title":"[Surgical treatment of thoracic aortic aneurysms: historical pages].","authors":"D S Panfilov, B N Kozlov","doi":"10.33029/1027-6661-2025-31-2-7-17","DOIUrl":"https://doi.org/10.33029/1027-6661-2025-31-2-7-17","url":null,"abstract":"<p><p>The article discusses the main historical events related to the diagnosis and treatment of thoracic aortic aneurysms, tracing the evolution of surgical approaches in patients with this pathology, as well as describing the facts and events that influenced the development of thoracic aortic surgery as an independent branch of cardiovascular surgery.</p>","PeriodicalId":7821,"journal":{"name":"Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery","volume":"31 2","pages":"7-17"},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147430245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1